Peter Lio, MD 

HCPLive Peter Lio, MD: RAD Preview

 continues to evolve at a rapid pace, the 

Revolutionizing Atopic Dermatitis (RAD) Annual Meeting

 remains a cornerstone for education, collaboration, and progress in patient care.

 has seen an explosion in interest and therapeutic advancement in recent years. There are more options than ever but figuring out how to use them in real life with real patients has made clinician education on the topic more important than ever.

“When you focus on a disease state, not only do you get reinforcement, you get a number of experts really taking you from the very beginning all the way up to the highest level discussions. You're going to get privy to some of the most interesting questions that everybody's wrestling with who's actually doing the research at the moment,” explained Peter Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine and founding director of Chicago Integrative Eczema Center, in an interview. “And for me, this is where I learned the most.”

At the RAD 2024 meeting, the community welcomed the presentation of LEVEL UP data, the Measure Up program, and the DELTA studies. Beyond updates in clinical trials and guideline adoption, the RAD annual meeting also shines a spotlight on other clinically relevant aspects of care, such as management of skin of color, comorbidity management, and more.

In this interview, Lio, who will be leading a session at the meeting, which takes place June 06-07, 2025 in Nashville, TN, talks about why RAD has become one of the most valuable meetings for anyone treating atopic dermatitis. He shares why the sessions, the speakers, and the conversations happening are different from other meetings through a specific focus on real-world challenges, patients, and optimizing care.

Relevant disclosures for Lio include AbbVie, Almirall, Arbonne, ASLAN Pharmaceuticals, Dermavant, Eli Lilly and Company, Galderma, Johnson & Johnson, L’Oreal, LEO Pharma, Pfizer, Regeneron/Sanofi Genzyme and others.

Campbell P. MJH Life Sciences Celebrates Acquisition of Revolutionizing Atopic Dermatitis (RAD) Annual Meeting. HCP Live. Published November 11, 2024. Accessed April 9, 2025. 

https://www.hcplive.com/view/mjh-life-sciences-celebrates-acquisition-of-revolutionizing-atopic-dermatitis-rad-annual-meeting

Videos

Peter Lio, MD, discusses the value of hyperfocused meetings such as RAD and what sessions he is most looking forward to at RAD 2025.

Previewing Revolutionizing Atopic Dermatitis 2025, with Peter Lio, MD

Considerations for Switching Treatment

Video content above is prompted by the following:

Would you consider a treatment switch in a patient with 75% improvement?

Panelists discuss whether a treatment switch would be considered for a patient with 75% improvement in atopic dermatitis, weighing the benefits of continued treatment versus the potential for further improvement with a different therapy.

Treatment Nonresponders in Atopic Dermatitis

How do you define treatment nonresponders in AD?

Panelists discuss how they define treatment non-responders in atopic dermatitis (AD), focusing on factors such as lack of significant improvement in symptoms, inadequate response to therapy, or failure to achieve treatment goals despite proper adherence and adjustments.

Lebrikizumab in Patients With Skin of Color (ADmirable)

AD is fairly common in patients with skin of color, but we have limited data with AD drugs in these patients.

Please discuss data from other studies, including any real-world data.

Panelists discuss the limited data on atopic dermatitis (AD) treatments in patients with skin of color, highlighting findings from other studies and real-world data to better understand treatment efficacy and safety in this diverse patient population.

Peter Lio, MD

Articles